CARLSBAD, Calif. — November 11, 2025 — Leads & Copy —
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today that management will participate in the following upcoming investor conferences:
The 16th Annual Craig-Hallum Alpha Select Conference will be held November 18, 2025, at the Sheraton New York Times Square Hotel.
The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum will be held November 20, 2025, at the Westin NY Grand Central, located at 212 E 42nd Street New York, NY 10017.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio.
The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring.
With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
Ryan Douglas
IR@exagen.com
760.560.1525
Source: Exagen Inc.
